The European Commission authorized Moderna’s mCOMBRIAX for adults 50+, giving the Cambridge company a key commercial win while U.S. approval remains unsettled.

Eli Lilly is reportedly in advanced talks to buy Boston‑based Kelonia Therapeutics for more than $2 billion, folding a promising in‑vivo CAR‑T program into Lilly’s pipeline.

Four Boston researchers were honored at the Breakthrough Prize gala for work from CRISPR cures to muon physics and Pantheon+. The awards spotlight local labs and long-term science.

A federal appeals court revived Teva’s patent fight with Eli Lilly and sent the case back to Massachusetts, reopening a dispute that once produced a $176.5M jury award.

PitchBook/NVCA tallies show Texas startups raised $5.8B in Q1 versus Massachusetts’ $5.3B, driven by several massive defense and robotics rounds in Austin. The reversal highlights how a few big deals can flip statewide VC rankings quickly.

Swedish AI startup Lovable opened a Downtown Crossing office at One Lincoln and plans to hire dozens for sales and customer roles.

Mass General Brigham researchers found plasma pTau217 rises years before amyloid shows on PET scans, offering a cheaper path to earlier Alzheimer's detection and trial recruitment.

Harbinger Health raised $100M to push a multi-cancer blood test toward launch. The Cambridge company says the tests will screen for about 12 cancers as it scales lab operations.

Seaport Therapeutics filed to go public, aiming to raise roughly $100M to advance its Glyph neuropsychiatry pipeline.

Wasabi has closed its acquisition of Seagate’s Lyve Cloud, folding the S3‑compatible platform into its hot‑cloud stack and accelerating its push into AI‑ready storage.

Life Biosciences closed an $80M Series D to fund a first-in-human ER-100 trial and expand its partial epigenetic reprogramming pipeline.

A federal judge found a customs officer wrongly revoked a Harvard researcher's visa after frog-embryo samples were found at Logan Airport, a decision with wide implications.

Gilead will acquire Munich-based Tubulis for $3.15B upfront, with up to $1.85B in milestones; the deal highlights Tubulis’ small Cambridge Innovation Center office.